Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 18, 2026.

Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions

Sheikh Taslim Ali, Lin Wang, Eric H. Y. Lau and 5 more

Science · 2020 · CC BY

doi:10.1126/science.abc9004

Abstract

From cough to splutter In epidemiology, serial intervals are measured from when one infected person starts to show symptoms to when the next person infected becomes symptomatic. For any specific infection, the serial interval is assumed to be a fixed characteristic. Using valuable transmission pair data for coronavirus disease (COVID-19) in mainland China, Ali et al. noticed that the average serial interval changed as nonpharmaceutical interventions were introduced. In mid-January 2020, serial intervals were on average 7.8 days, whereas in early February 2020, they decreased to an average of 2.2 days. The more quickly infected persons were identified and isolated, the shorter the serial interval became and the fewer the opportunities for virus transmission. The change in serial interval may not only measure the effectiveness of infection control interventions but may also indicate rising population immunity. Science , this issue p. 1106

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

In December 2019, a novel coronavirus disease [coronavirus disease 2019 (COVID-19)], caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, China. It has since spread to more than 212 countries, causing more than 10 million confirmed cases and 500,000 deaths worldwide as of 30 June 2020. Recent studies have suggested that several demographic and social factors can influence the transmission of COVID-19, including age- and gender-related differences in infection risk, reduced risk of infection as a result of intensive nonpharmaceutical interventions (NPIs) (e.g., isolation and social distancing), and abrupt changes in social mixing patterns because of lockdowns and confinement. Serial interval, defined as the duration between the symptom-onset time of the infector and that of the infectee, is an essential metric for estimating many other key epidemiological parameters (e.g., reproduction number, generation time, and attack rate), which are used in turn to predict disease trends and health care demands. In early studies, before the availability of specific data on COVID-19, the serial interval distribution of COVID-19 was assumed to be similar to those of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS), with a mean >8 days. Once specific data became available on COVID-19 transmission pairs, several studies examined the serial interval distribution of COVID-19 in different locations, with estimates of the mean serial interval varying from 3.1 to 7.5 days. All of these studies have assumed that the timing of transmission events can be described by a single, stable distribution of serial intervals at different stages of an epidemic.

In fact, the serial interval depends on the incubation period, the profile of infectiousness after infection, and the variation in contact structure of the population (as explained in fig. S1). The incubation period describes the biological process of disease progression and tends to follow a more similar distribution from one location to another, with minor variations resulting from social or cultural differences in how symptoms are perceived or reported. However, the profile of infectiousness over time can vary because of human behavior. Changes in contact patterns and the use of public health measures can reshape the timing of infection events by limiting successful contacts overall (e.g., social distancing) or after illness onset (e.g., case isolation). Interventions such as the isolation of confirmed and suspected cases, suspension of intra- and intercity travel, and different forms of social distancing were widely implemented in different Chinese cities. This provides an opportunity to study the temporal changes in the serial interval distribution and its association with NPIs. Here, we show that variation in the serial interval can occur and has important implications for the assessment of transmission dynamics and the impact of control measures.

We compiled a database of 1407 COVID-19 transmission pairs, in which symptom-onset dates and social relationships were available for both the infector and infectee of 677 transmission pairs [see table S1 for entire database and supplementary materials for details]. Household and nonhousehold transmissions were identified on the basis of the information on social relationships (e.g., familial members of the same household, nonhousehold relatives, colleagues, classmates, friends, and other face-to-face contacts). The data were reconstructed from the publicly available reports of 9120 confirmed COVID-19 cases reported by 27 provincial and 264 urban health commissions in China outside Hubei province. Data from Hubei province were excluded because there was less reliable information on chains of transmission during the widespread community circulation of COVID-19; outside Hubei province, it was more straightforward to link connected cases and derive serial intervals. We focused on 677 transmission pairs with infectors having developed symptoms from 9 January through 13 February 2020. This 36-day period spans a series of key interventions related to the evolving epidemiology and transmission dynamics of COVID-19 in mainland China.

We first calculated the number of transmission pairs in our database by the onset dates of infectors (fig. S3). Because many infectors (339) developed symptoms during 23 to 29 January 2020, we defined this 1-week period as the peak week, the previous 14-day period (9 to 22 January 2020) as the prepeak period, and the following 15-day period (30 January to 13 February 2020) as the postpeak period. We computed the serial interval as the number of days between the symptom-onset date of the infector and that of the infectee for each transmission pair. Empirical serial interval distributions for transmission pairs, counting from symptom onsets of the infectors during each period, indicate that the serial intervals shortened over time (Fig. 1A).

We estimated the serial interval distribution during each nonoverlapping period by fitting a normal distribution to the corresponding serial intervals data (supplementary materials). Analysis of all 677 transmission pairs revealed that the serial interval distribution had a mean of 5.1 [95% credibility interval (CrI): 4.7, 5.5] days and a standard deviation (SD) of 5.3 (95% CrI: 5.0, 5.6) days (table S2) overall, which is consistent with other recent studies. However, fitting to data of nonoverlapping periods of time revealed considerable variation in serial interval distributions (Fig. 1B). Before the peak, the mean and SD of serial intervals were estimated to be 7.8 (7.0, 8.6) days and 5.2 (4.7, 5.9) days, respectively. During the peak, the mean and SD reduced to 5.1 (4.6, 5.7) days and 5.0 (4.6, 5.4) days, respectively. After the peak, these estimates further shortened to 2.6 (1.9, 3.2) days and 4.6 (4.2, 5.1) days, respectively (table S2).

Next, we examined the real-time change in serial intervals by using a series of running time windows with fixed lengths of 10, 14, or 18 days (fig. S10). In contrast to the use of a constant distribution of serial intervals, our analysis suggests that serial intervals were gradually shortened over the study period (Fig. 2A), which is robust to alternative specifications of time windows (fig. S10). By fitting the transmission pairs data for each running time window by Markov chain Monte Carlo (MCMC) (Fig. 2A and table S3), we estimated that during the first 14-day period (9 to 22 January 2020), the serial intervals were longer on average [mean: 7.8 (95% CrI: 7.0, 8.6) days; SD: 5.2 (95% CrI: 4.7, 5.9) days]; whereas during the last 14 days (30 January to 13 February 2020), the serial intervals were much shorter on average [mean: 2.2 (1.5, 2.9) days; SD: 4.6 (4.1, 5.1) days]. Notably, the mean serial intervals were shortened by more than a factor of 3 over the 36-day period.

The transmission pair data also contain information for age, sex, household, and isolation delay (i.e., time duration from symptom onset to isolation) for most infectors. This allows for a granular stratification. Using either nonoverlapping or running time windows for data stratified by each of these factors, we find the same pattern of shorter serial intervals over time (Figs. 1B and 2A and tables S2 and S3). Therefore, we termed this changing serial interval the effective serial interval, which accounts for temporal changes caused by its potential driving factors. Notably, the length of effective serial intervals is positively associated with the length of isolation delay (Fig. 2A; figs. S5, S6, and S9; and tables S3 and S4), which accounts for the decreasing isolation delay over time (fig. S2). Therefore, early isolation (shorter than the median isolation delay) translates into shorter serial intervals [mean: 3.3 (2.7, 3.8) days; SD: 4.5 (4.1, 4.9) days], and delayed isolation (longer than the median isolation delay) is associated with longer serial intervals [mean: 6.8 (6.2, 7.3) days; SD: 5.3 (4.9, 5.7) days] (table S2). Stratification by age, gender, or household shows no clear differences in serial interval estimates. Our findings are robust to using alternative distributions (e.g., Gumbel distribution) for model fitting (fig. S11) and the infector-based approach (fig. S14).

Our probabilistic, individual-based simulated and regression models confirm that serial intervals are positively associated with isolation delay (section 5, supplementary materials). We found that the serial intervals become shorter on the basis of how much faster the infectors are isolated, regardless of when an infector starts to be infectious before symptom onset (fig. S5). In an individual-based simulation model with a mean generation time of 7.8 days, the simulated mean serial intervals are reduced from ~8.0 to ~1.2 days when the isolation delay is reduced from 10 to 0 days. We found through regression models that up to 51.5% of the variability in daily empirical serial interval can be explained by isolation delay and further improved by other NPI factors, which explain an additional 15.6 to 16.7% of the variability (table S5).

In practice, the time-varying serial interval may affect the estimation of epidemic parameters, including the transmissibility. The real-time transmissibility of an infectious disease is often characterized by the instantaneous reproduction number (Rt), which is defined as the expected number of secondary infections caused by an infector on day t. The pathogen spreads when Rt > 1 and is under control when Rt < 1. To examine the effect of serial intervals on Rt, we first obtained the daily number of cases on the basis of the onset dates of infectors and infectees among the 1407 transmission pairs (Fig. 2, B to D). By applying the statistical method developed by Cori et al., we estimated Rt for each day between 20 January and 13 February 2020. We noticed substantial differences in estimates of Rt between using a single stable serial interval distribution and time-varying effective serial interval distributions. The magnitude of this difference is more prominent during the prepeak and postpeak periods than it is during the peak week when Rt ≈ 1 (Fig. 2, B to D).

We observed that the serial interval for COVID-19 in mainland China was shortened by more than a factor of 3 in the 36 days between 9 January and 13 February 2020. This reduction was driven by intensive NPIs, particularly the reduction of the isolation delay period. Isolation of an infector 1 day earlier is expected to reduce the mean serial interval by 0.7 days. Thus, the serial interval was shortened by >3 days if infectors were rapidly isolated (Figs. 1B and 2A and tables S2 and S3). This is consistent with advocating isolation of cases and quarantining contacts within 1 day from symptom onset, which has been estimated to reduce COVID-19 transmission by 60%. We have not identified any substantial effects of gender or age of infectors on serial interval, but the NPIs were found to be significant for the transmission in communities rather than in households (table S5). Other studies have estimated that the infectiousness of COVID-19 is greater at symptom onset. Although a short serial interval indicates that a substantial proportion of transmission events have occurred by the time symptoms are apparent, because of prolonged viral shedding case isolation is still likely to reduce further transmission. Changes in the serial interval can therefore indicate effective implementation of specific transmission-reduction measures.

There are some limitations to our work. First, it is possible that there was recall bias on the onset of first symptoms in the line-list data; however, given the centralized pandemic response in mainland China, we expected that recall bias would not affect our main conclusions (figs. S12 and S13). Second, other factors may have influenced the reduction of effective serial intervals, as we can only explain up to 72% of the variance in observed serial intervals. Finally, our current transmission pair data do not contain variables about the potential exposure window of each case, which do not allow further inferences on the transmission potential.

Our results indicate that caution is needed when attempting to generalize estimates of the serial interval distribution to other places or to other periods of time in the same place, for example when estimating instantaneous reproductive numbers (Fig. 2, B to D). The real-time metric of effective serial intervals indicates that transmission models also need to account for the temporal variation in serial intervals as an epidemic proceeds. Effective serial intervals may provide better measurements of instantaneous transmissibility (Rt)—because they include the effects of possible drivers of transmission—and could be helpful to policy-makers because they offer real-time information on the impact of public health measures.

References 49

  1. 1.

    World Health Organization (WHO), “Coronavirus disease 2019 (‎COVID-19)‎: Situation report – 162” (WHO, 2020); www.who.int/docs/default-source/coronaviruse/situation-reports/20200629-covid-19-sitrep-161.pdf?sfvrsn=74fde64e_2.

    Not in our library

  2. 2.
  3. 3.

    C. Wenham, J. Smith, R. Morgan, Gender and COVID-19 Working Group, COVID-19: The gendered impacts of the outbreak. Lancet 395, 846–848 (2020 ).

    Not in our library10.1016/s0140-6736(20)30526-2

  4. 4.
  5. 5.

    J. Hellewell, S. Abbott, A. Gimma, N. I. Bosse, C. I. Jarvis, T. W. Russell, J. D. Munday, A. J. Kucharski, W. J. Edmunds, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, S. Funk, R. M. Eggo, Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob. Health 8, e488–e496 (2020 ).

    Not in our library10.1016/s2214-109x(20)30074-7

  6. 6.
  7. 7.
  8. 8.

    R. M. Anderson, H. Heesterbeek, D. Klinkenberg, T. D. Hollingsworth, How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet 395, 931–934 (2020 ).

    Not in our library10.1016/s0140-6736(20)30567-5

  9. 9.

    J. R. Koo, A. R. Cook, M. Park, Y. Sun, H. Sun, J. T. Lim, C. Tam, B. L. Dickens, Interventions to mitigate early spread of SARS-CoV-2 in Singapore: A modelling study. Lancet Infect. Dis. 20, 678–688 (2020 ).

    Not in our library10.1016/s1473-3099(20)30162-6

  10. 10.
  11. 11.

    M. A. Vink, M. C. Bootsma, J. Wallinga, Serial intervals of respiratory infectious diseases: A systematic review and analysis. Am. J. Epidemiol. 180, 865–875 (2014 ).

    Not in our library10.1093/aje/kwu209

  12. 12.

    J. T. Wu, K. Leung, G. M. Leung, Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. Lancet 395, 689–697 (2020 ).

    Not in our library10.1016/s0140-6736(20)30260-9

  13. 13.

    M. Chinazzi, J. T. Davis, M. Ajelli, C. Gioannini, M. Litvinova, S. Merler, A. Pastore Y Piontti, K. Mu, L. Rossi, K. Sun, C. Viboud, X. Xiong, H. Yu, M. E. Halloran, I. M. Longini Jr.., A. Vespignani, The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science 368, 395–400 (2020 ).

    Not in our library10.1126/science.aba9757

  14. 14.
  15. 15.
  16. 16.
  17. 17.

    Q. Li, X. Guan, P. Wu, X. Wang, L. Zhou, Y. Tong, R. Ren, K. S. M. Leung, E. H. Y. Lau, J. Y. Wong, X. Xing, N. Xiang, Y. Wu, C. Li, Q. Chen, D. Li, T. Liu, J. Zhao, M. Liu, W. Tu, C. Chen, L. Jin, R. Yang, Q. Wang, S. Zhou, R. Wang, H. Liu, Y. Luo, Y. Liu, G. Shao, H. Li, Z. Tao, Y. Yang, Z. Deng, B. Liu, Z. Ma, Y. Zhang, G. Shi, T. T. Y. Lam, J. T. Wu, G. F. Gao, B. J. Cowling, B. Yang, G. M. Leung, Z. Feng, Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N. Engl. J. Med. 382, 1199–1207 (2020 ).

    Not in our library10.1056/nejmoa2001316

  18. 18.

    J. M. Griffin, A. B. Collins, K. Hunt, D. McEvoy, M. Casey, A. W. Byrne, C. G. McAloon, A. Barber, E. A. Lane, S. J. More, A rapid review of available evidence on the serial interval and generation time of COVID-19. medRxiv 2020.05.08.20095075 [Preprint]. 11 May 2020..

    Not in our library10.1101/2020.05.08.20095075

  19. 19.

    S. Ma, J. Zhang, M. Zeng, Q. Yun, W. Guo, Y. Zheng, S. Zhao, M. H. Wang, Z. Yang, Epidemiological parameters of coronavirus disease 2019: A pooled analysis of publicly reported individual data of 1155 cases from seven countries. medRxiv 2020.03.21.20040329 [Preprint]. 24 March 2020..

    Not in our library10.1101/2020.03.21.20040329

  20. 20.

    X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan, X. Tan, X. Mo, Y. Chen, B. Liao, W. Chen, F. Hu, Q. Zhang, M. Zhong, Y. Wu, L. Zhao, F. Zhang, B. J. Cowling, F. Li, G. M. Leung, Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 26, 672–675 (2020 ).

    Not in our library10.1038/s41591-020-0869-5

  21. 21.

    Q. Bi, Y. Wu, S. Mei, C. Ye, X. Zou, Z. Zhang, X. Liu, L. Wei, S. A. Truelove, T. Zhang, W. Gao, C. Cheng, X. Tang, X. Wu, Y. Wu, B. Sun, S. Huang, Y. Sun, J. Zhang, T. Ma, J. Lessler, T. Feng, Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study. Lancet Infect. Dis. 20, 911–919 (2020 ).

    Not in our library10.1016/s1473-3099(20)30287-5

  22. 22.
  23. 23.

    Lin, PDGLin/COVID19_EffSerialInterval_NPI: Serial interval of SARS-CoV-2 was shortened over time by non-pharmaceutical interventions, version v1.0, Zenodo (2020);.

    Not in our library10.5281/zenodo.3940300

  24. 24.
  25. 25.

    K. Leung, J. T. Wu, D. Liu, G. M. Leung, First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: A modelling impact assessment. Lancet 395, 1382–1393 (2020 ).

    Not in our library10.1016/s0140-6736(20)30746-7

  26. 26.

    A. Pan, L. Liu, C. Wang, H. Guo, X. Hao, Q. Wang, J. Huang, N. He, H. Yu, X. Lin, S. Wei, T. Wu, Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. JAMA 323, 1915–1923 (2020 ).

    Not in our library10.1001/jama.2020.6130

  27. 27.

    J. Zhang, M. Litvinova, W. Wang, Y. Wang, X. Deng, X. Chen, M. Li, W. Zheng, L. Yi, X. Chen, Q. Wu, Y. Liang, X. Wang, J. Yang, K. Sun, I. M. Longini Jr.., M. E. Halloran, P. Wu, B. J. Cowling, S. Merler, C. Viboud, A. Vespignani, M. Ajelli, H. Yu, Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: A descriptive and modelling study. Lancet Infect. Dis. 20, 793–802 (2020 ).

    Not in our library10.1016/s1473-3099(20)30230-9

  28. 28.

    A. Cori, N. M. Ferguson, C. Fraser, S. Cauchemez, A new framework and software to estimate time-varying reproduction numbers during epidemics. Am. J. Epidemiol. 178, 1505–1512 (2013 ).

    Not in our library10.1093/aje/kwt133

  29. 29.

    L. Zou, F. Ruan, M. Huang, L. Liang, H. Huang, Z. Hong, J. Yu, M. Kang, Y. Song, J. Xia, Q. Guo, T. Song, J. He, H.-L. Yen, M. Peiris, J. Wu, SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N. Engl. J. Med. 382, 1177–1179 (2020 ).

    Not in our library10.1056/nejmc2001737

  30. 30.

    Y. Pan, D. Zhang, P. Yang, L. L. M. Poon, Q. Wang, Viral load of SARS-CoV-2 in clinical samples. Lancet Infect. Dis. 20, 411–412 (2020 ).

    Not in our library10.1016/s1473-3099(20)30113-4

  31. 31.

    X. K. Xu, X.-F. Liu, Y. Wu, S. T. Ali, Z. Du, P. Bosetti, E. H. Y. Lau, B. J. Cowling, L. Wang, Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection. Clin. Infect. Dis. 10.1093/cid/ciaa790 (2020 ).

    Not in our library10.1093/cid/ciaa790

  32. 32.

    P. Trapman, F. Ball, J.-S. Dhersin, V. C. Tran, J. Wallinga, T. Britton, Inferring R0 in emerging epidemics-the effect of common population structure is small. J. R. Soc. Interface 13, 20160288 (2016 ).

    Not in our library10.1098/rsif.2016.0288

  33. 33.

    S. W. Park, D. Champredon, J. Dushoff, Inferring generation-interval distributions from contact-tracing data. J. R. Soc. Interface 17, 20190719 (2020 ).

    Not in our library10.1098/rsif.2019.0719

  34. 34.

    Q. H. Liu, M. Ajelli, A. Aleta, S. Merler, Y. Moreno, A. Vespignani, Measurability of the epidemic reproduction number in data-driven contact networks. Proc. Natl. Acad. Sci. U.S.A. 115, 12680–12685 (2018 ).

    Not in our library10.1073/pnas.1811115115

  35. 35.

    Y. Bai, L. Yao, T. Wei, F. Tian, D.-Y. Jin, L. Chen, M. Wang, Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA 323, 1406–1407 (2020 ).

    Not in our library10.1001/jama.2020.2565

  36. 36.

    X. Pan, D. Chen, Y. Xia, X. Wu, T. Li, X. Ou, L. Zhou, J. Liu, Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect. Dis. 20, 410–411 (2020 ).

    Not in our library10.1016/s1473-3099(20)30114-6

  37. 37.

    M. M. Arons, K. M. Hatfield, S. C. Reddy, A. Kimball, A. James, J. R. Jacobs, J. Taylor, K. Spicer, A. C. Bardossy, L. P. Oakley, S. Tanwar, J. W. Dyal, J. Harney, Z. Chisty, J. M. Bell, M. Methner, P. Paul, C. M. Carlson, H. P. McLaughlin, N. Thornburg, S. Tong, A. Tamin, Y. Tao, A. Uehara, J. Harcourt, S. Clark, C. Brostrom-Smith, L. C. Page, M. Kay, J. Lewis, P. Montgomery, N. D. Stone, T. A. Clark, M. A. Honein, J. S. Duchin, J. A. Jernigan, Public Health–Seattle and King County and CDC COVID-19 Investigation Team, Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N. Engl. J. Med. 382, 2081–2090 (2020 ).

    Not in our library10.1056/nejmoa2008457

  38. 38.
  39. 39.
  40. 40.
  41. 41.

    R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A. Müller, D. Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brünink, J. Schneider, R. Ehmann, K. Zwirglmaier, C. Drosten, C. Wendtner, Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020 ).

    Not in our library10.1038/s41586-020-2196-x

  42. 42.
  43. 43.
  44. 44.

    M. Lipsitch, T. Cohen, B. Cooper, J. M. Robins, S. Ma, L. James, G. Gopalakrishna, S. K. Chew, C. C. Tan, M. H. Samore, D. Fisman, M. Murray, Transmission dynamics and control of severe acute respiratory syndrome. Science 300, 1966–1970 (2003 ).

    Not in our library10.1126/science.1086616

  45. 45.
  46. 46.

    J. Wallinga, P. Teunis, Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am. J. Epidemiol. 160, 509–516 (2004 ).

    Not in our library10.1093/aje/kwh255

  47. 47.
  48. 48.

    Z. Li, Q. Chen, L. Feng, L. Rodewald, Y. Xia, H. Yu, R. Zhang, Z. An, W. Yin, W. Chen, Y. Qin, Z. Peng, T. Zhang, D. Ni, J. Cui, Q. Wang, X. Yang, M. Zhang, X. Ren, D. Wu, X. Sun, Y. Li, L. Zhou, X. Qi, T. Song, G. F. Gao, Z. Feng, China CDC COVID-19 Emergency Response Strategy Team, Active case finding with case management: The key to tackling the COVID-19 pandemic. Lancet 396, 63–70 (2020 ).

    Not in our library10.1016/s0140-6736(20)31278-2

  49. 49.

Cited by papers we hold 11

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.